Salmeterol/Fluticasone Cipla
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Salmeterol/Fluticasone Cipla 25 micrograms/125 micrograms /dose pressurised inhalation, suspension
Salmeterol/Fluticasone Cipla 25 micrograms/250 micrograms /dose pressurised inhalation, suspension
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each metered dose of Salmeterol/Fluticasone Ciplaprovides:
25 micrograms of salmeterol (as salmeterol xinafoate) and 125 or 250 micrograms of fluticasone propionate (delivered from the valve). This is equivalent to 21 micrograms of salmeterol and 110 or 220 micrograms of fluticasone propionate delivered from the actuator (delivered dose).
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Pressurised inhalation, suspension.
The canister contains a white homogeneous suspension.
4. CLINICAL PARTICULARS
Therapeutic indications
Salmeterol/Fluticasone Ciplais indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist
or
- patients already adequately controlled on both inhaled corticosteroids and long-acting beta-2-agonist.
4.2 Posology and method of administration
Salmeterol/Fluticasone Cipla is for inhalation use only.
Patients should be made aware that Salmeterol/Fluticasone Cipla must be used daily for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the strength of Salmeterol/Fluticasone Cipla they are receiving remains optimal and is only changed on medical advice. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.
Where the control of symptoms is maintained with the lowest strength of Salmeterol/Fluticasone Cipla (25/125 microgram), the next step could include a swap to a different inhaled salmeterol fluticasone product available in a lower strength (25/50 micrograms).
Patients should be given the strength of Salmeterol/Fluticasone Cipla containing the appropriate fluticasone propionate dosage for the severity of their disease.
Prescribers should be aware that, in patients with asthma, fluticasone propionate is as effective as other inhaled steroids at approximately half the microgram daily dose. If an individual patient should require dosages outside the recommended regimen, appropriate doses of beta-agonist and/or corticosteroid should be prescribed.
Recommended Doses:
Adults and adolescents 12 years and older:
Two inhalations of 25 micrograms salmeterol and 125 micrograms fluticasone propionate twice daily.
Two inhalations of 25 micrograms salmeterol and 250 micrograms fluticasone propionate twice daily.
A clear benefit has not been shown as compared to inhaled fluticasone propionate alone used as initial maintenance therapy when one or two of the criteria of severity are missing. In general inhaled corticosteroids remain the first line treatment for most patients. Salmeterol/Fluticasone Cipla is not intended for the initial management of mild asthma.
Use of a spacer device with Salmeterol/Fluticasone Ciplais recommended in patients who have, or are likely to have difficulties to coordinate actuation with inspiration.
A spacer device such as the Volumatic or AeroChamber Plus or other spacer devices can be used (depending on National Guidance). Single dose pharmacokinetic data have demonstrated that the systemic exposure to salmeterol and fluticasone propionate may change when different spacer devices are used (see section 4.4).
Patients should be instructed in the proper use and care of their inhaler and spacer and their technique checked to ensure optimum delivery of the inhaled drug to the lungs. Patients should continue to use the same make of spacer device as switching between spacer devices can result in changes in the dose delivered to the lungs (see section 4.4). Re-titration to the lowest effective dose should always follow the introduction or change of a spacer device.
Special patient groups:
There is no need to adjust the dose in elderly patients or in those with renal impairment. There are no data available for use of Salmeterol/Fluticasone Cipla in patients with hepatic impairment.
Instructions for Use:
Patients should be instructed in the proper use of their inhaler (see patient information leaflet)
During inhalation, the patient should preferably sit or stand. The inhaler has been designed for use in a vertical position.
Testing the Inhaler:
Before using for the first time patients should remove the mouthpiece cover by gently squeezing the sides of the cover, shake the inhaler well, hold the inhaler between the fingers and thumb with your thumb at the base, below the mouthpiece and release four puffs into the air to make sure that it works. The inhaler should be shaken immediately before releasing each puff. If the inhaler has not been used for a week or more remove the mouthpiece cover, the patients should shake the inhaler well and release two puffs into the air.
Use of the inhaler:
1. Patients should remove the mouthpiece cover by gently squeezing the sides of the cover
2. Patients should check inside and outside of the inhaler including the mouthpiece for the presence of loose objects.
3. Patients should shake the inhaler well to ensure that any lose objects are removed and that the contents of the inhaler are evenly mixed
4. Patients should hold the inhaler upright between fingers and thumb with their thumb on the base, below the mouthpiece.
5. Patients should breathe out as far as is comfortable and then place the mouthpiece in their mouth between their teeth and close their lips around it, Patients should be instructed not to bite the mouth piece.
6. Just after starting to breathe in through their mouth, patients should press firmly down on the top of the inhaler to release Salmeterol/Fluticasone Ciplawhile still breathing in steadily and deeply.
7. While holding their breath, patients should take the inhaler from their mouth and take their finger from the top of the inhaler. Patients should continue holding their breath for as long as is comfortable.
8. To take a second inhalation, patients should keep the inhaler upright and wait about half a minute before repeating steps 3 to7.
9. Patients should immediately replace the mouthpiece cover in the correct orientation by firmly pushing and snapping the cap intoposition. The cover does not require excessive force and it will click into position.
IMPORTANT
Patients should not rush stages 5, 6 and 7. It is important that patients start to breathe in as slowly as possible just before operating their inhaler. Patients should practice in front of a mirror for the first few times. If they see "mist" coming from the top of their Inhaler or the sides of their mouth they should start again from stage 2.
Patients should geta replacement when the indicator shows the number ‘40’ and the colour on the dose indicator will change from green to red. Stop using the inhaler when the indicator shows ‘0’ as any puffs left in the device may not be enough to give you a full dose. Never try to alter the numbers on the indicator or detach the indicator from the actuator. The indicator cannot be reset and is permanently attached to the actuator.
Cleaning:
Your Inhaler should be cleaned at least once a week.
1. Remove the mouth piece cover.
2. Do not remove the canister from the plastic casing.
3. Wipe the inside and outside of the mouthpiece and the plastic casing with a dry cloth or tissue.
4. Replace the mouthpiece cover in the correct orientation. The cover does not require excessive force and it will click into position.
DO NOT PUT THE METAL CONTAINER IN WATER
4.3 Contraindications
Salmeterol/Fluticasone Ciplais contraindicated in patients with hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
The management of asthma should normally follow a stepwise programme and patient response should be monitored clinically and by lung function tests.
Salmeterol/Fluticasone Cipla should not be used to treat acute asthma symptoms for which a fast and short acting bronchodilator is required. Patients should be advised to have their medicinal product to be used for relief in an acute asthma attack available at all times.
Patients should not be initiated on Salmeterol/Fluticasone Cipla during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
Serious asthma-related adverse events and exacerbations may occur during treatment with Salmeterol/Fluticasone Cipla Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Salmeterol/Fluticasone Cipla
Increasing use of short-acting bronchodilators to relieve asthma symptoms indicates deterioration of asthma control and patients should be reviewed by a physician.
Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should undergo urgent medical assessment. Consideration should be given to increasing corticosteroid therapy. The patient should also be medically reviewed where the current dosage of Salmeterol/Fluticasone Cipla has failed to give adequate control of asthma. Consideration should be given to additional corticosteroid therapies.
Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Salmeterol/Fluticasone Cipla Regular review of patients as treatment is stepped down is important. Treatment with Salmeterol/Fluticasone Cipla should not be stopped abruptly.
As with all inhaled medication containing corticosteroids, Salmeterol/Fluticasone Cipla should be administered with caution in patients with pulmonary tuberculosis.
Rarely, Salmeterol/Fluticasone Cipla may cause cardiac arrhythmias e.g. supraventricular tachycardia, extrasystoles and atrial fibrillation, and a mild transient reduction in serum potassium at high therapeutic doses. Therefore Salmeterol/Fluticasone Cipla should be used with caution in patients with severe cardiovascular disorders, heart rhythm abnormalities, diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or patients predisposed to low levels of serum potassium.
There have been very rare reports of increases in blood glucose levels (See section 4.8) and this should be considered when prescribing to patients with a history of diabetes mellitus.
As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. Salmeterol/Fluticasone Cipla should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Care should be taken when transferring patients to Salmeterol/Fluticasone Cipla therapy, particularly if there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy.
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression. It is important, therefore, that the patient is reviewed regularly and the dose of inhaledcorticosteroid is reduced to the lowest dose at which effective control of asthma is maintained.
Prolonged treatment of patients with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crisis. Very rare cases of adrenal suppression and acute adrenal crisis have also been described with doses of Fluticasone propionate between 500 and less than 1000 micrograms. Situations, which could potentially trigger acute adrenal crisis, include
trauma, surgery, infection or any rapid reduction in dosage. Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, hypotension, decreased level of consciousness, hypoglycaemia, and seizures. Additional systemic corticosteroid cover should be considered during periods of stress or elective
surgery.
Systemic absorption of salmeterol and fluticasone propionate is largely through the lungs. As the use of a spacer device with a metered dose Inhaler may increase drug delivery to the lungs it should be noted that this could potentially lead to an increase in the risk of systemic adverse effects. Single dose pharmacokinetic data have demonstrated that the systemic exposure to
salmeterol and fluticasone propionate may change when the different spacer devices are used. Salmeterol/Fluticasone Cipla
The benefits of inhaled fluticasone propionate therapy should minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Patients who have required high dose emergency corticosteroid therapy in the past may also be at risk. This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered. The extent of the adrenal impairment may require specialist advice before elective procedures.
Ritonavir can greatly increase the concentration of fluticasone propionate in plasma. Therefore, concomitant use should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects. There is also an increased risk of systemic side effects when combining fluticasone propionate with other potent CYP3A inhibitors (see section4.5).
An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.
There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.
Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.
Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.
Data from a large clinical trial (the Salmeterol Multi-Center Asthma Research Trial, SMART) suggested African-American patients were at increased risk of serious respiratory-related events or deaths when using salmeterol compared with placebo (see section 5.1). It is not known if this was due to pharmacogenetic or other factors. Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remained uncontrolled or worsen whilst using Salmeterol/Fluticasone Cipla.
Concomitant use of systemic ketoconazole significantly increases systemic exposure to salmeterol. This may lead to an increase in the incidence of systemic effects (e.g. prolongation in the QTc interval and palpitations). Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors should therefore be avoided unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment (see section 4.5).
Paediatric population
Adolescents taking high doses of fluticasone propionate (typically ≥ 1000 micrograms/day) may be at particular risk of systemic effects. Systemic effects may occur, particularly at high doses prescribed for long periods. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, acute adrenal crisis and growth
retardation in adolescents and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression.
It is recommended that the height of adolescents receiving prolonged treatment with inhaled corticosteroid is regularly monitored.
The dose of inhaled corticosteroid should be reduced to the lowest dose at which effective control of asthma is maintained.
Interaction with other medicinal products and other forms of interaction
Both non-selective and selective beta-blockers should be avoided in patients with asthma, unless there are compelling reasons for their use.
Concomitant use of other beta-adrenergic containing drugs can have a potentially additive effect.
Fluticasone Propionate
Under normal circumstances, low plasma concentrations of fluticasone propionate are achieved after inhaled dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 in the gut and liver. Hence, clinically significant drug interactions mediated by fluticasone propionate are unlikely.
In an interaction study in healthy subjects with intranasal fluticasone propionate, ritonavir (a highly potent cytochrome P450 3A4 inhibitor) 100 mg b.i.d. increased the fluticasone propionate plasma concentrations several hundred fold, resulting in markedly reduced serum cortisol concentrations. Information about this interaction is lacking for inhaled fluticasone propionate, but a marked increase in fluticasone propionate plasma levels is expected. Cases of Cushing's syndrome and adrenal suppression have been reported. The combination should be avoided unless the benefit outweighs the increased risk of systemic glucocorticoid side-effects.
In a small study in healthy volunteers, the slightly less potent CYP3A inhibitor ketoconazole increased the exposure of fluticasone propionate after a single inhalation by 150%. This resulted in a greater reduction of plasma cortisol as compared with fluticasone propionate alone. Co-treatment with other potent CYP3A inhibitors, such as itraconazole, is also expected to increase the systemic fluticasone propionate exposure and the risk of systemic side-effects. Caution is recommended and longterm treatment with such drugs should if possible be avoided.
Salmeterol
Potent CYP3A4 inhibitors
Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 micrograms inhaled twice daily) in 15 healthy subjects for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold Cmax and 15-fold AUC). This may lead to an increase in the incidence of other systemic effects of salmeterol treatment (e.g. prolongation of QTc interval and
palpitations) compared with salmeterol or ketoconazole treatment alone (see Section 4.4).
Clinically significant effects were not seen on blood pressure, heart rate, blood glucose and blood potassium levels. Coadministration with ketoconazole did not increase the elimination half-life of salmeterol or increase salmeterol accumulation with repeat dosing.
The concomitant administration of ketoconazole should be avoided, unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment. There is likely to be a similar risk of interaction with other potent CYP3A4 inhibitors (e.g. itraconazole, telithromycin, ritonavir).
Moderate CYP 3A4 inhibitors
Co-administration of erythromycin (500mg orally three times a day) and salmeterol (50 micrograms inhaled twice daily) in 15 healthy subjects for 6 days resulted in a small but non-statistically significant increase in salmeterol exposure (1.4-fold Cmax and 1.2-fold AUC). Co-administration with erythromycin was not associated with any serious adverse effects.
Fertility, pregnancy and lactation
Fertility
There are no data in humans. However, animal studies showed no effects of salmeterol or fluticasone propionate on fertility.
Pregnancy
A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity of salmeterol and fluticasone propionate. Animal studies have shown reproductive toxicity after administration of beta-2-adrenoreceptor agonists and glucocorticosteroids (see section 5.3).
Administration of Salmeterol/Fluticasone Cipla to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
The lowest effective dose of fluticasone propionate needed to maintain adequate asthma control should be used in the treatment of pregnant women.
Lactation
It is unknown whether salmeterol and fluticasone propionate/metabolites are excreted in human milk. Studies have shown that salmeterol and fluticasone propionate, and their metabolites, are excreted into the milk of lactating rats.
A risk to breastfed newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinueSalmeterol/Fluticasone Cipla therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
4.7 Effects on ability to drive and use machines
No studies of the effect on the ability to drive and use machines have been performed.
4.8 Undesirable effects
As Salmeterol/Fluticasone Cipla contains salmeterol and fluticasone propionate, the type and severity of adverse reactions associated with each of the compounds may be expected. There is no incidence of additional adverse events following concurrent administration of the two compounds.
Adverse events which have been associated with salmeterol/fluticasone propionate are given below, listed by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (<1/10,000) and not known (cannot be estimated from the available data). Frequencies were derived from clinical
trial data. The incidence in placebo was not taken into account.
|
System Organ Class |
Adverse Event |
Frequency |
|
Infections & Infestations |
Candidiasis of the mouth and throat Pneumonia (in COPD patients) Bronchitis |
Common Common1,3 Common1,3 |
|
Immune System Disorders |
Hypersensitivity reactions with the following manifestations: Cutaneous hypersensitivity reactions Angioedema (mainly facial and oropharyngeal oedema) Respiratory symptoms (dyspnoea) Respiratory symptoms (bronchospasm) Anaphylactic reactions including anaphylactic shock |
Uncommon Rare Uncommon Rare Rare |
|
Endocrine Disorders |
Cushing's syndrome, Cushingoid features, Adrenal suppression, Growth retardation in children and adolescents, Decreased bone mineral density |
Rare4 |
|
Metabolism & Nutrition Disorders |
Hypokalaemia Hyperglycaemia |
Common3 Uncommon4 |
|
Psychiatric Disorders |
Anxiety Sleep disorders Behavioural changes, including hyperactivity and irritability (predominantly in children) Depression, aggression (predominantly in children) |
Uncommon Uncommon Rare Not Known |
|
Nervous System Disorders |
Headache Tremor |
Very Common1 Uncommon |
|
Eye disorder |
Cataract Glaucoma |
Uncommon Rare4 |
|
Cardiac Disorders |
Palpitations Tachycardia Cardiac arrhythmias (including supraventricular tachycardia and extrasystoles). Atrial fibrillation Angina pectoris |
Uncommon Uncommon Rare Uncommon Uncommon |
|
Respiratory, Thoracic & Mediastinal Disorders |
Nasopharyngitis Throat irritation Hoarseness/dysphonia Sinusitis Paradoxical bronchospasm |
Very Common2,3 Common Common Common1,3 Rare4 |
|
Skin and subcutaneous tissue disorders |
Contusions |
Common1,3 |
|
Musculoskeletal & Connective Tissue Disorders |
Muscle cramps Traumatic fractures Arthralgia Myalgia |
Common Common1,3 Common Common |
1. Reported commonly in placebo
2. Reported very commonly in placebo
3. Reported over 3 years in a COPD study
4. See section 4.4
Description of selected adverse reactions
The pharmacological side effects of beta-2-agonist treatment, such as tremor, palpitations and headache, have been reported, but tend to be transient and reduce with regular therapy.
Due to the fluticasone propionate component, hoarseness and candidiasis (thrush) of the mouth and throat can occur in some patients. Both hoarseness and incidence of candidiasis may be relieved by gargling with water after using the product. Symptomatic candidiasis can be treated with topical anti-fungal therapy whilst still continuing with the Salmeterol/Fluticasone Cipla
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/ risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting systems listed in Appendix V*.
4.9 Overdose
There are no data available from clinical trials on overdose with <product name, however data on overdose with both drugs are given below:
The signs and symptoms of salmeterol overdose are tremor, headache and tachycardia. The preferred antidotes are cardioselective beta-blocking agents, which should be used with caution in patients with a historyof bronchospasm. If Salmeterol/Fluticasone Cipla therapy has to be withdrawn due to overdose of the beta agonist component of the drug, provision of appropriate replacement steroid therapy should be considered. Additionally, hypokalaemia can occur and potassium replacement should be considered.
Acute: Acute inhalation of fluticasone propionate doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not need emergency action as adrenal function is recovered in a few days, as verified by plasma cortisol measurements.
Chronic overdose of inhaled fluticasone propionate: Refer to section 4.4: risk of adrenal suppression.
Monitoring of adrenal reserve may be necessary. In cases of fluticasone propionate overdose Salmeterol/Fluticasone Cipla therapy may still be continued at a suitable dosage for symptom control.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic Group: Adrenergics and other anti-asthmatics.
ATC Code: R03AK06
Salmeterol and Fluticasone pressurised inhalation suspension Asthma clinical trials
A twelve month study (Gaining Optimal Asthma ControL, GOAL), in 3416 adult and adolescent patients with persistent asthma, compared the safety and efficacy of Salmeterol and Fluticasone pressurised inhalation suspension versus inhaled corticosteroid (Fluticasone Propionate) alone to determine whether the goals of asthma management were achievable. Treatment was stepped up every 12 weeks until **Total control was achieved or the highest dose of study drug was reached. GOAL showed more patients treated with Salmeterol and Fluticasone pressurised inhalation suspension achieved asthma control than patients treated with ICS alone and this control was attained at a lower corticosteroid dose
Well-Controlled asthma was achieved more rapidly with Salmeterol and Fluticasone pressurised inhalation suspension than with ICS alone. The time on treatment for 50% of subjects to achieve a first individual Well-Controlled week was 16 days for Salmeterol and Fluticasone pressurised inhalation suspension compared to 37 days for the ICS group. In the subset of steroid naive asthmatics the time to an individual Well Controlled week was 16 days in the Salmeterol and Fluticasone pressurised inhalation suspension treatment compared to 23 days following treatment with ICS.
The overall study results showed:
|
Percentage of Patients Attaining *Well Controlled (WC) and **Totally Controlled (TC) Asthma over 12 months |
||||
|
|
Salmeterol/FP |
FP |
||
|
Pre-Study Treatment |
WC |
TC |
WC |
TC |
|
No ICS (SABA alone) |
78% |
50% |
70% |
40% |
|
Low dose ICS (≤500 microgram BDP or equivalent/day) |
75% |
44% |
60% |
28% |
|
Medium dose ICS (>500-1000 microgram BDP or equivalent/day) |
62% |
29% |
47% |
16% |
|
Pooled results across the 3 treatment levels |
71% |
41% |
59% |
28% |
*Well controlled asthma; occasional symptoms or SABA use or less than 80% predicted lung function plus no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy
**Total control of asthma; no symptoms, no SABA use, greater than or equal to 80% predicted lung function, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy
A double-blind, randomised, parallel group study in 318 patients with persistent asthma aged ≥18 years evaluated the safety and tolerability of administering two inhalations twice daily (double dose) of Salmeterol and Fluticasone pressurised inhalation suspension for two weeks. The study showed that doubling the inhalations of each strength of Salmeterol and Fluticasone pressurised inhalation suspension for up to 14 days resulted in a small increase in beta-agonist-related adverse events (tremor; 1 patient [1%] vs 0, palpitations; 6 [3%] vs 1 [<1%], muscle cramps; 6[3%] vs 1 [<1%]) and a similar incidence of inhaled corticosteroid related adverse events (e.g. oral candidiasis; 6 [6%] vs 16 [8%], hoarseness; 2 [2%] vs 4 [2%]) compared to one inhalation twice daily. The small increase in beta-agonist-related adverse events should be taken into account if doubling the dose of Salmeterol and Fluticasone pressurised inhalation suspension is considered by the physician in adult patients requiring additional short-term (up to 14 days) inhaled corticosteroid therapy.
The Salmeterol Multi-center Asthma Research Trial (SMART)
SMART was a multi-centre, randomised, double-blind, placebo-controlled, parallel group 28-week study in the US which randomised 13,176 patients to salmeterol (50μg twice daily) and 13,179 patients to placebo in addition to the patients' usual asthma therapy. Patients were enrolled if ≥12 years of age, with asthma and if currently using asthma medication (but not a LABA). Baseline ICS use at study entry was recorded, but not required in the study. The primary endpoint in SMART was the combined number of respiratory-related deaths and respiratory-related life-threatening experiences.
Key findings from SMART: primary endpoint
|
Patient group |
Number of primary endpoint events /number of patients |
Relative Risk (95% confidence intervals) |
|
|
salmeterol |
placebo |
||
|
All patients |
50/13,176 |
36/13,179 |
1.40 (0.91, 2.14) |
|
Patients using inhaled steroids |
23/6,127 |
19/6,138 |
1.21 (0.66, 2.23) |
|
Patients not using inhaled steroids |
27/7,049 |
17/7,041 |
1.60 (0.87, 2.93) |
|
African-American patients |
20/2,366 |
5/2,319 |
4.10 (1.54, 10.90) |
(Risk in bold is statistically significant at the 95% level.)
Key findings from SMART by inhaled steroid use at baseline: secondary endpoints
|
|
Number of secondary endpoint events /number of patients |
Relative Risk (95% confidence intervals) |
|
|
|
salmeterol |
placebo |
|
|
Respiratory -related death |
|||
|
Patients using inhaled steroids |
10/6127 |
5/6138 |
2.01 (0.69, 5.86) |
|
Patients not using inhaled steroids |
14/7049 |
6/7041 |
2.28 (0.88, 5.94) |
|
Combined asthma-related death or life-threatening experience |
|||
|
Patients using inhaled steroids |
16/6127 |
13/6138 |
1.24 (0.60, 2.58) |
|
Patients not using inhaled steroids |
21/7049 |
9/7041 |
2.39 (1.10, 5.22) |
|
Asthma-related death |
|||
|
Patients using inhaled steroids |
4/6127 |
3/6138 |
1.35 (0.30, 6.04) |
|
Patients not using inhaled steroids |
9/7049 |
0/7041 |
* |
(*=could not be calculated because of no events in placebo group. Risk in bold figures is statistically significant at the 95% level. The secondary endpoints in the table above reached statistical significance in the whole population.) The secondary endpoints of combined all-cause death or life-threatening experience, all cause death, or all cause hospitalisation did not reach statistical significance in the whole population.
Mechanism of action:
Salmeterol/Fluticasone Cipla contains salmeterol and fluticasone propionate which have differing modes of action.
The respective mechanisms of action of both drugs are discussed below.
Salmeterol:
Salmeterol is a selective long-acting (12 hour) beta-2-adrenoceptor agonist with a long side chain which binds to the exo-site of the receptor.
Salmeterol produces a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting beta-2-agonists.
Fluticasone propionate:
Fluticasone propionate given by inhalation at recommended doses has a glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, with less adverse effects than when corticosteroids are administered systemically.
5.2 Pharmacokinetic properties
When salmeterol and fluticasone propionate were administered in combination by the inhaled route, the pharmacokinetics of each component were similar to those observed when the drugs were administered separately. For pharmacokinetic purposes therefore each component can be considered separately.
Salmeterol:
Salmeterol acts locally in the lung therefore plasma levels are not an indication of therapeutic effects. In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma due to the low plasma concentrations at therapeutic doses (approximately 200 picogram/ml or less) achieved after inhaled dosing.
Fluticasone propionate:
The absolute bioavailability of a single dose of inhaled fluticasone propionate in healthy subjects varies between approximately 5-11% of the nominal dose depending on the inhalation device used. In patients with asthma a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed.
Systemic absorption occurs mainly through the lungs and is initially rapid then prolonged. The remainder of the inhaled dose may be swallowed but contributes minimally to systemic exposure due to the low aqueous solubility and pre-systemic metabolism, resulting in oral availability of less than 1%. There is a linear increase in systemic exposure with increasing inhaled dose.
The disposition of fluticasone propionate is characterised by high plasma clearance (1150ml/min), a large volume of distribution at steady-state (approximately 300l) and a terminal half-life of approximately 8 hours.
Plasma protein binding is 91%.
Fluticasone propionate is cleared very rapidly from the systemic circulation. The main pathway is metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4. Other unidentified metabolites are also found in the faeces. The renal clearance of fluticasone propionate is negligible. Less than 5% of the dose is excreted in urine, mainly as metabolites.
The main part of the dose is excreted as faeces as metabolites and unchanged drug.
5.3 Preclinical safety data
The only safety concerns for human use derived from animal studies of salmeterol and fluticasone propionate given separately were effects associated with exaggerated pharmacological actions.
In animal reproduction studies, glucocorticosteroids have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant for man given recommended doses. Animal studies with salmeterol have shown embryofoetal toxicity only at high exposure levels. Following co-administration, increased incidences of transposed umbilical artery and incomplete ossification of occipital bone were found in rats at doses associated with known glucocorticoid-induced abnormalities. The non-CFC propellant, Norflurane, has been shown to have no toxic effect at very high vapour concentrations, far in excess of those likely to be experienced by patients, in a wide range of animal species exposed daily for periods of two years.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Norflurane (HFA 134a).
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
2 years
6.4 Special precautions for storage
Replace the mouthpiece cover firmly and snap it into position.
The canister contains a pressurised liquid. Store below 300C. Do not expose to temperatures higher than 50°C. Do not pierce the canister.
As with most inhaled medicinal products in pressurised containers, the therapeutic effect of this medicinal product may decrease when the container is cold.
Nature and contents of container
Aluminium canister with a suitable metering valve and a polypropylene actuator with dust cap having dose indicator in a sealed pouch containing desiccant.
Each container is filled to deliver 120 doses.
Pack sizes:
1, 2 (bundled package 2x1) or 3 (bundled package 3x1) canisters containing 120 doses.
10 (bundled package 10x1) canisters containing 120 doses -hospital/pharmacy use only
Not all pack sizes may be marketed.
No special requirements.
7. MARKETING AUTHORISATION HOLDER
Cipla Europe NV
Uitbreidingstraat 80,
2600 Antwerp,
Belgium
8. MARKETING AUTHORISATION NUMBER(S)
<[To be completed nationally]>
9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
<[To be completed nationally]>
10. DATE OF REVISION OF THE TEXT
4 November 2016